|Print Page Close Window|
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
05/02/17MyoKardia to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017
NASDAQ GS | MYOK (Common Stock)
$13.90 + 0.45
07/20/174:04 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.